{"filing":{"accession_number":"0001193125-26-343482","cik":"0001719714","ticker":"MREO","company_name":"Mereo BioPharma Group plc","form":"8-K","filing_date":"2026-08-11","report_date":"2026-08-11","primary_document":"mreo-20260811.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1719714/000119312526343482/mreo-20260811.htm"},"events":[{"id":26910,"run_id":24477,"accession_number":"0001193125-26-343482","anchor_item_number":"1.01","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.92,"summary":"Mereo entered into an Option and License Agreement with Sentynl Therapeutics granting Sentynl exclusive U.S. commercial rights to alvelestat while Mereo retains rest-of-world rights and leads global development. The agreement includes $40 million in upfront and R\u0026D payments, up to $435 million in milestone payments, and double-digit royalties on U.S. sales.","company_name":"Mereo BioPharma Group plc","ticker":"MREO","filing_date":"2026-08-11","form":"8-K","submitted_at":null,"items":[{"id":28206,"accession_number":"0001193125-26-343482","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.92,"reasoning":"Mereo entered into an Option and License Agreement with Sentynl Therapeutics granting Sentynl exclusive U.S. commercial rights to alvelestat while Mereo retains rest-of-world rights and leads global development. The agreement includes $40 million in upfront and R\u0026D payments, up to $435 million in milestone payments, and double-digit royalties on U.S. sales. This is a material definitive agreement involving significant licensing, development, and commercialization rights that would materially affect investor assessment of the company's asset portfolio and revenue potential.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-11T12:08:53.468619+00:00","company_name":"","ticker":null,"filing_date":""},{"id":28207,"accession_number":"0001193125-26-343482","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.92,"reasoning":"The Item 7.01 disclosure references an \"Agreement discussed in Item 1.01\" and the press release announces an \"option and license agreement\" between Mereo and Sentynl Therapeutics for alvelestat. This is a material licensing and commercialization partnership involving significant financial terms ($40 million upfront/R\u0026D payments, up to $435 million in milestones, and double-digit royalties), grant of U.S. commercial rights to a partner, and global manufacturing rights. While structured as an option agreement rather than an outright acquisition, this represents a material M\u0026A-type activity—a significant disposition of commercial rights and strategic partnership that would affect investor assessment of the company's asset portfolio and revenue potential.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-11T12:08:53.468619+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":28206,"accession_number":"0001193125-26-343482","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.92,"reasoning":"Mereo entered into an Option and License Agreement with Sentynl Therapeutics granting Sentynl exclusive U.S. commercial rights to alvelestat while Mereo retains rest-of-world rights and leads global development. The agreement includes $40 million in upfront and R\u0026D payments, up to $435 million in milestone payments, and double-digit royalties on U.S. sales. This is a material definitive agreement involving significant licensing, development, and commercialization rights that would materially affect investor assessment of the company's asset portfolio and revenue potential.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-11T12:08:53.468619+00:00","company_name":"Mereo BioPharma Group plc","ticker":"MREO","filing_date":"2026-08-11"},{"id":28207,"accession_number":"0001193125-26-343482","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.92,"reasoning":"The Item 7.01 disclosure references an \"Agreement discussed in Item 1.01\" and the press release announces an \"option and license agreement\" between Mereo and Sentynl Therapeutics for alvelestat. This is a material licensing and commercialization partnership involving significant financial terms ($40 million upfront/R\u0026D payments, up to $435 million in milestones, and double-digit royalties), grant of U.S. commercial rights to a partner, and global manufacturing rights. While structured as an option agreement rather than an outright acquisition, this represents a material M\u0026A-type activity—a significant disposition of commercial rights and strategic partnership that would affect investor assessment of the company's asset portfolio and revenue potential.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-11T12:08:53.468619+00:00","company_name":"Mereo BioPharma Group plc","ticker":"MREO","filing_date":"2026-08-11"}]}